Katti Jessen

Katti Jessen has extensive experience in the field of translational sciences and oncology research and development. Katti is currently serving as the Senior Vice President of Translational Sciences at Solve Therapeutics, Inc. Prior to this, they worked as the Executive Director of Translational Research, Oncology R&D at VelosBio Inc., which was later acquired by Merck. Before that, they held the position of Executive Director of Translational Science at Oncternal Therapeutics.

Katti'sexpertise in translational oncology also includes previous roles at Pfizer, where they worked as the Director of Translational Oncology in the Early Oncology Development and Clinical Research department. Katti also worked as an Associate Director of Oncology Drug Discovery and Development at eFFECTOR Therapeutics, Inc. and Takeda Oncology.

Katti's career began at Sanford-Burnham Medical Research Institute as a Post Doc. Katti then progressed to various positions in discovery biology and oncology drug discovery at SGX Pharmaceuticals, Maxim Pharmaceuticals (acquired by Epicept), and Intellikine Inc. (acquired by Millennium/Takeda Oncology).

Overall, Katti Jessen's work experience spans over two decades and showcases their in-depth knowledge of translational sciences and their significant contributions to the field of oncology research and development.

Katti Jessen has a Bachelor's degree from the University of California, Davis, where they majored in Biochemistry and minored in German. Katti also holds a Ph.D. in Molecular and Cellular Biology from the same institution.